Biperiden for prevention of post-traumatic epilepsy: A protocol of a double-blinded placebo-controlled randomized clinical trial (BIPERIDEN trial)
Carregando...
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
FORESTI, Maira Licia
PINHEIRO, Carla Cristina Gomes
PACHECO, Rafael Leite
RIERA, Rachel
Citação
PLOS ONE, v.17, n.9, article ID e0273584, 11p, 2022
Resumo
Background Traumatic brain injury (TBI) is one of the most important causes of acquired structural epilepsy, post-traumatic epilepsy (PTE), however, efficient preventative measures and treatment are still not available to patients. Preclinical studies indicated biperiden, an anticholinergic drug, as a potential drug to modify the epileptogenic process. The main objective of this clinical trial is to evaluate the efficacy of biperiden as an antiepileptogenic agent in patients that suffered TBI. Methods This prospective multicenter (n = 10) interventional study will include 312 adult patients admitted to emergency care units with a diagnosis of moderate or severe TBI. Following inclusion and exclusion criteria, patients will be randomized, using block randomization, to receive double-blind treatment with placebo or biperiden for 10 days. Follow-up will occur at specific time windows up to 2 years. Main outcomes are incidence of PTE after TBI and occurrence of severe adverse events. Other outcomes include exploratory investigation of factors that might have benefits for the treatment or might influence its results, such as genetic background, clinical progression, electroencephalographic abnormalities, health-related quality of life and neuropsychological status. Analyses will be conducted following the safety, intention-to-treat and efficacy concepts. Discussion We hypothesize that biperiden treatment will be effective to prevent or mitigate the development of post-traumatic epilepsy in TBI patients. Other health measures from this population also may benefit from treatment with biperiden.
Palavras-chave
Referências
- Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104
- Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x
- Benassi SK, 2021, SEIZURE-EUR J EPILEP, V90, P99, DOI 10.1016/j.seizure.2021.02.031
- Bittencourt S, 2017, EPILEPSY RES, V138, P88, DOI 10.1016/j.eplepsyres.2017.10.019
- Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
- Cincura C, 2009, CEREBROVASC DIS, V27, P119, DOI 10.1159/000177918
- Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022
- French JA, 2021, EPILEPSIA OPEN, V6, P483, DOI 10.1002/epi4.12526
- Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x
- Furtado MD, 2012, NEUROTOXICOLOGY, V33, P1476, DOI 10.1016/j.neuro.2012.09.001
- Gamble C, 2017, JAMA-J AM MED ASSOC, V318, P2337, DOI 10.1001/jama.2017.18556
- Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
- Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
- HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x
- Howick J, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003294
- International Conference on Harmonisation of Technical Requirement for Registration of Pharmaceuticals for Human Use, 1994, CLIN SAFETY DATA MAN
- LERNER P F, 1960, South Med J, V53, P465
- Meller S, 2021, NEUROBIOL DIS, V158, DOI 10.1016/j.nbd.2021.105446
- Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7
- Pocock SJ, 1983, CLIN TRIALS PRACTICA, P123
- Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0
- Salazar Andres M, 2015, Handb Clin Neurol, V128, P525, DOI 10.1016/B978-0-444-63521-1.00033-9
- Saletti PG, 2019, NEUROBIOL DIS, V123, P86, DOI 10.1016/j.nbd.2018.06.017
- Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13
- TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801